vaccine efficacy ranged from a low of 9.6% for infection confirmed by laboratory measure only to 58.7% for infection confirmed both by laboratory measure and by the presence of at least one RSV symptom of grade ≥2, and the differences in infection incidence between the treatment groups were not statistically significant. When infection was defined instead by quantifiable qRT-PCR viral load, efficacy ranged from 51.8% to 79.3%, and differences in symptomatic infection were statistically significant. Finally, when defined by virus culture results alone, vaccine efficacy was 88.5% (p=0.0125); addition of clinical symptoms to the definition did not improve efficacy.
There was a larger phase 2 w 400+ patients but I couldn't find any data. however the results of this call it phase 2b trial did get them BTD and Prime, so I am assuming the data was relatively strong
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.